Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. ADVM-022 is a single, in-office intravitreal injection gene therapy. ADVM-022 is being developed for the treatment of patients with chronic retinal diseases who respond to anti-vascular endothelial growth factor therapy, including wet age-related macular degeneration and diabetic macular edema. ADVM-022 utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. The ADVM stock yearly return is shown above.
The yearly return on the ADVM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ADVM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|